Results 31 to 40 of about 1,634 (161)

Two-season effectiveness of a single nirsevimab dose against RSV hospitalisation in healthy term-born infants: a population-based case–control study, Spain, October 2023 to March 2025 [PDF]

Eurosurveillance
BACKGROUND In autumn 2023, Spain recommended nirsevimab to all infants born after 1 April 2023, as catch-up or at-birth immunisation. AIM We estimated effectiveness of a single nirsevimab dose against respiratory syncytial virus (RSV) hospitalisations ...
the Nirsevimab Effectiveness Study Collaborators
doaj   +2 more sources

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

Nature Communications, 2023
Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV) fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV ...
Bahar Ahani, Kevin M. Tuffy, Anastasia A. Aksyuk, Deidre Wilkins, Michael E. Abram, Ron Dagan, Joseph B. Domachowske, Johnathan D. Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir A. Madhi, Vaishali S. Mankad, Eric A. F. Simões, Benjamin Sparklin, Scott D. Speer, Ann Marie Stanley, David E. Tabor, Ulrika Wählby Hamrén, Elizabeth J. Kelly, Tonya Villafana   +20 more
doaj   +1 more source

Recommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children [PDF]

Clinical and Experimental Pediatrics
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections (LRTIs) in infants and young children. In April 2024, the Korea Ministry of Food and Drug Safety approved nirsevimab (Beyfortus), a long-acting monoclonal ...
Soo-Han Choi, Dong Hyun Kim, Jong Gyun Ahn, Ki Wook Yun, Byung-Wook Eun, Jin Lee, Jina Lee, Taek-Jin Lee, Hyunju Lee, Dae Sun Jo, Eun Young Cho, Hye-Kyung Cho, Young June Choe, Ui Yoon Choi, Yun-Kyung Kim, The Committee on Infectious Diseases of the Korean Pediatric Society   +15 more
doaj   +1 more source

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection

Frontiers in Immunology, 2023
IntroductionNirsevimab is an extended half-life (M252Y/S254T/T256E [YTE]-modified) monoclonal antibody to the pre-fusion conformation of the respiratory syncytial virus (RSV) Fusion protein, with established efficacy in preventing RSV-associated lower ...
Tyler Brady, Corinne Cayatte, Tiffany L. Roe, Scott D. Speer, Hong Ji, LeeAnn Machiesky, Tianhui Zhang, Deidre Wilkins, Kevin M. Tuffy, Elizabeth J. Kelly   +9 more
doaj   +1 more source

Cost-effectiveness and public health impact of RSV immunization for all infants in Japan: a mixed strategy with nirsevimab and RSVpreF

Expert Review of Vaccines
Background Respiratory syncytial virus (RSV) remains a leading cause of medically attended lower respiratory tract disease (MA-LRTD) among infants in Japan.
Naruhiko Ishiwada, Xinyu Wang, Takeshi Arashiro, Camille Reygrobellet, Benjamin Yarnoff, Robert Musci, Mehdi Ghemmouri   +6 more
doaj   +1 more source

Multicentre study on nirsevimab: Bayesian analysis reveals persisting risk for preterm infants

BMJ Paediatrics Open
Objective To evaluate whether the timing and effectiveness of nirsevimab prophylaxis vary by gestational age.Design Retrospective cohort study conducted during two identical epidemic seasons: 2023–2024 (before nirsevimab introduction) and 2024–2025 ...
Federico Marchetti, Enrico Valletta, Gianluca Vergine, Silvia Bloise, Gina Ancora, Enrico Cocchi, Aurora Lorefice, Sara Zannoni, Benedetta Pellegrini, Francesco Saverio Morlupo, Beatrice Scarpellini, Melodie Olivia Loredana Rosa Aricò, Francesco Accomando, Marcello Stella   +13 more
doaj   +1 more source

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

New England Journal of Medicine, 2020
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants. Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscular dose.In this trial ...
Madhi, Shabir A., Domachowske, Joseph B., Takas, Therese, Yuan, Yuan, Griffin, M. Pamela, Devincenzo, John P., Villafana, Tonya, Dubovsky, Filip, Khan, Anis A., Esser, Mark T., Simoes, Eric A. F., Manzoni, Paolo   +11 more
openaire   +5 more sources

A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults

Clinical and Translational Science
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) in infants worldwide. Nirsevimab, an extended half‐life monoclonal antibody against RSV, is approved in China for the prevention of RSV lower respiratory ...
Xiaomeng Mao, Xiaohan Hua, Chengyi Wu, Xiaoyun Ge, Jie Zhang, Xiaojie Wu, Robert J. Kubiak, Ulrika Wählby Hamrén, Tonya Villafana, Georgios Christou, Jannine Green, Therese Takas, Yuwen Jin   +12 more
doaj   +1 more source

Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in FranceResearch in context

EClinicalMedicine
Summary: Background: To evaluate the acceptance and safety of the treatment of newborns with nirsevimab (a long-acting monoclonal antibody designed to prevent respiratory syncytial virus infections) during the first season of implementation.
Charlotte Ocana de Sentuary, Clara Testard, Marion Lagrée, Maxime Leroy, Lisa Gasnier, Alicia Enes-Dias, Constance Leruste, Diariatou Diallo, Michael Génin, Thameur Rakza, François Dubos   +10 more
doaj   +1 more source

Respiratory Syncytial Virus Vaccination Is Associated With Increased Odds of Preterm Birth

Acta Paediatrica, EarlyView.
ABSTRACT Aim To analyse whether respiratory syncytial virus (RSV) vaccination during pregnancy increases the odds of preterm birth. Methods A rapid review and meta‐analysis was performed. The main outcome was the risk of preterm (gestational week less than 37) birth.
Ilari Kuitunen, Marjut Haapanen
wiley   +1 more source